BioSyntech Inc.
TSX VENTURE : BSY

BioSyntech Inc.

October 30, 2006 07:00 ET

BioSyntech Shares Begins Trading on the TSX Today

LAVAL, QUEBEC--(CCNMatthews - Oct. 30, 2006) - BioSyntech, Inc.(TSX VENTURE:BSY) ("BioSyntech" or the "Company") is pleased to announce that its common shares will commence trading on the Toronto Stock Exchange ("TSX") at the open of trading today, Monday October 30, 2006 under the symbol "BSY".

The common shares of BioSyntech which were listed and traded on the Toronto Venture Exchange ("TSX-V") are delisted and will cease to be traded on the TSX-V today, as a result of the Company's graduation to the TSX.

"Our graduation to the TSX is an important milestone for us as we continue with the development of our three lead products, BST-CarGel, BST-DermOn and BST-InPod", stated Claude LeDuc, President and CEO of BioSyntech. "The listing of our shares on the TSX will enhance our visibility in the public markets and make our Company shares accessible to a new group of institutional and retail investors."

About BioSyntech

BioSyntech is a biotechnology company specializing in the discovery, development and manufacturing of innovative, cost-effective, and physician-friendly biotherapeutic thermogels for regenerative medicine and therapeutic delivery. BioSyntech's Quality Management System is registered to ISO 9001:2000 standard. For additional information, visit www.biosyntech.com.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Contact Information

  • BioSyntech, Inc.
    François Michaud
    Chief Financial Officer
    450-686-2437, ext. 260
    or
    The Equicom Group Inc.
    Eric Bouchard
    514-844-7997
    ebouchard@equicomgroup.com